Epicept Corporation - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Epicept Corporation. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Epicept Corporation. The Group's principal activity is to develop and commercialize pharmaceutical products for the treatment of cancer and pain. The lead product is Ceplene(R), which when used concomitantly with interleukin-2 or IL-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia or AML for adult patients who are in their first complete remission. In addition to Ceplene(R), it has two oncology compounds and a pain product candidate for the treatment of peripheral neuropathies in clinical development. Its cancer portfolio includes Crinobulin, or EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors and lymphomas. Its late-stage pain product candidate, EpiCeptTM NP-1 Cream is a prescription topical analgesic cream designed to provide effective long-term relief of pain associated with peripheral neuropathies. It operates in the Unites States and Germany.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report